The agency takes other steps to make COVID-19 tests more available.
Formulary Watch
Latest News
All News
Advertisement
New measures taken due to depression, suicidal thoughts, and other adverse events.
Discover the latest news on COVID-19 vaccine and drug development.
Companies cited over false coronavirus claims include The Jim Bakker Show.
Isatuximab-irfc (Sarclisa, Sanofi-Aventis) was approved in combination with pomalidomide and dexamethason to treat adult patients with multiple myeloma who have received at least two prior therapies.
Inhaler is the first generic approval of its kind.
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
Treatment is first non-statin LDL-C lowering treatment approved in years.
Eisai disagrees with FDA decision.
Treatments include meds for arthritis pain and allergy eye drops.
Advertisement
Treatment will be first to target a specific type of advanced lung cancer.
FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.
FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.
Global market for peanut allergy treatments estimate at $4.5 billion.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
Novel cancer drug snags FDA approval.
Traditional party drug known as ecstasy is undergoing clinical trials to assist in PTSD treatment.
Lamotrigine was contaminated with a heart drug.
Ozempic’s approval follows Jardiance’s expanded heart indication last July.
Already approved for adult patients, Fiasp is now available for children.
Major depression drug recalled over wrong dosage.
Pfizer bucks the trend with as high as 98.5% price cuts.
Approval of Ubrelvy follows several new migraine drugs.
Diabetes and hypertension are among the primary diseases included.
The fish oil drug is approved to reduce cardiovascular risk.
Alkermes omitted warnings about serious risks from taking the drug.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
Prior authorization isn’t shrinking. Its savings are
5